686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY
Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Yun‐Jung Choi(CymaBay Therapeutics (United States)), Marlyn J. Mayo(Southwestern Medical Center), Mitchell L. Shiffman(Bon Secours Health System), Christoph Berg, Klara Dickinson, John M. Vierling(Baylor College of Medicine), Sandrin C. Bergheanu, Aliya Gulamhusein(Toronto General Hospital), Aparna Goel(Stanford University), Charles Landis(University of Washington), Gideon M. Hirschfield(University Health Network), Christopher L. Bowlus(University of California, Davis), Richard Aspinall(Queen Alexandra Hospital), Marcus‐Alexander Wörns, Adam Peyton, Tarek Hassanein, Charles A. McWherter(University Health Network), Stuart C. Gordon(United States Department of Veterans Affairs), Alexandra Steinberg(CymaBay Therapeutics (United States)), Pol Boudes(CymaBay Therapeutics (United States)), Paul J. Thuluvath(University of Maryland, Baltimore), Cynthia Levy(University of Miami), Palak Trivedi(University Hospitals Birmingham NHS Foundation Trust), Lynsey Corless(University of Hull), Peter Buggisch(Institute for Interdisciplinary Medicine), Mark G. Swain(University of Calgary), David Sheridan, Joseph A. Odin(University of Pittsburgh), Carmen Stanca, Stephen A. Harrison(Pinnacle Clinical Research), Yu Li(China Medical University), Mónika Varga(CymaBay Therapeutics (United States)), David Jones(Memorial Sloan Kettering Cancer Center), Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), David Bernstein, Guy Neff, Bruce R. Bacon(Saint Louis University), Michael Galambos, Ke Yang(Northwestern Polytechnical University), Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Douglas Thorburn(Royal Free London NHS Foundation Trust)
Cited by 1
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k